Diabetes medicines that help the kidneys also reduced kidney disease progression in trial patients without diabetes.
Yes: in the combined placebo-controlled trials, people without diabetes who had chronic kidney disease or heart failure had about a one-third lower relative risk of kidney disease progression with SGLT2 inhibitors than with placebo. Serious ketoacidosis was rare and mainly occurred in people with diabetes, and no excess amputation risk was seen in the studied kidney-disease group without diabetes.
Lancet ·
Open the full explanation